From the start, our vision has been to create a bridge into the new world, a world without lung cancer. To reach this vision, the company would forge a path to address the contemporary unmet clinical need of early lung cancer diagnostics and prepare for future minimally invasive treatments.


In 2017, Body Vision received FDA clearance for LUNGVISION™ System and in 2018 the FDA clearance for LUNGVISION™ Disposable Tool. By November 2018 Body Vision accomplished over 400 clinical procedures


Body Vision Medical was founded in 2014 by Dorian Averbuch. Averbuch pioneered, developed and commercialized a novel electromagnetic navigation bronchoscopy approach at superDimension, where he learned about the broad field of interventional pulmonology and the specific challenges of early stage lung cancer.

Body Vision leaders saw the promise of existing electromagnetic systems, but they provided only a partial solution due to technical limitations, high utilization and maintenance costs, lack of integration with existing technologies and tools, and a long learning curve.

The company developed a better solution: a suite of LUNGVISION™ products and tools to reach suspicious nodules in the deep periphery of the lungs accurately and reliably that allows seamless utilization and integration with a variety of existing off-the- shelf operational tools and modalities.

Through continuous collaboration between physicians, clinical specialists and engineers of different specialties, Body Vision has focused on pioneering the new standard of care for lung diagnostics. Once verified for diagnostics, the LUNGVISION™ approach will be used to introduce surgical markers for VATS or radio-surgery and, later, for minimally invasive treatment tools such as radiofrequency or microwave ablation.